EGFR and cancer: Cetuximab, a chimerized monoclonal antibody to EGFR, specifically bind to the EGFR with high affinity by occluding the ligand-binding region, blocking ligand-induced EGFR tyrosine kinase activation and subsequent signal-transduction events leading to cancer cell proliferation9,11,12.